CN116549543B - Compound antioxidant product containing American ginseng and preparation method and application thereof - Google Patents

Compound antioxidant product containing American ginseng and preparation method and application thereof Download PDF

Info

Publication number
CN116549543B
CN116549543B CN202310689265.6A CN202310689265A CN116549543B CN 116549543 B CN116549543 B CN 116549543B CN 202310689265 A CN202310689265 A CN 202310689265A CN 116549543 B CN116549543 B CN 116549543B
Authority
CN
China
Prior art keywords
parts
american ginseng
powder
mixing
root
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202310689265.6A
Other languages
Chinese (zh)
Other versions
CN116549543A (en
Inventor
刘辉
陈云
和嘉杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yunnan Runcangsheng Technology Co ltd
Original Assignee
Yunnan Runcangsheng Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yunnan Runcangsheng Technology Co ltd filed Critical Yunnan Runcangsheng Technology Co ltd
Priority to CN202310689265.6A priority Critical patent/CN116549543B/en
Publication of CN116549543A publication Critical patent/CN116549543A/en
Application granted granted Critical
Publication of CN116549543B publication Critical patent/CN116549543B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/13—Coniferophyta (gymnosperms)
    • A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/40—Cornaceae (Dogwood family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/69—Polygalaceae (Milkwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725—Ziziphus, e.g. jujube
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/90—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in food processing or handling, e.g. food conservation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a compound antioxidation product containing American ginseng, which is prepared by extracting the following components in parts by weight: 20-30 parts of American ginseng, 15-25 parts of prepared rehmannia root, 20-28 parts of dogwood, 15-25 parts of baical skullcap root, 15-25 parts of gardenia, 8-12 parts of safflower, 18-22 parts of szechuan lovage rhizome, 20-26 parts of bitter orange, 18-25 parts of grassleaf sweetflag rhizome, 10-20 parts of polygala tenuifolia, 16-26 parts of platycladi seed and 15-25 parts of wild jujube seed. Is prepared through the steps of screening, cleaning, crushing, weighing, alcohol extraction, water extraction, concentration and the like. Compared with the prior art, the invention has the beneficial effects that: the components are synergistic, and the Chinese medicinal preparation has the effects of treating root and treating the root cause of senile dementia by the effects of replenishing qi to invigorate the spleen, nourishing the liver and kidney, clearing away heart-fire and toxic materials, promoting blood circulation and promoting qi circulation, and is beneficial to leaching out the effective components by adopting a reasonable leaching mode; because the components of the invention are nontoxic common medicinal materials, the invention has no harm to the body and no side effect after being used.

Description

Compound antioxidant product containing American ginseng and preparation method and application thereof
Technical Field
The invention relates to the technical field of medical treatment, in particular to a compound antioxidant product containing American ginseng and a preparation method and application thereof.
Background
Alzheimer's disease (senile dementia) is a degenerative disease of the central nervous system that occurs in the elderly and in the pre-senile stages and is characterized by progressive cognitive dysfunction and behavioral impairment, and by the deposition of Abeta to form neuronal plaques and neurofibrillary tangles formed by hyperphosphorylated Tau protein. The onset of AD is closely related to aβ -mediated oxidative stress. Currently, treatment is performed by methods such as drug therapy or non-drug therapy.
1. Drug treatment: senile dementia, also called Alzheimer's disease, is currently incurable and can only be treated to delay the progression of the disease. The patient can improve the cognitive function by taking medicines such as donepezil, rivastigmine or galantamine, and can improve the brain metabolism by taking medicines such as oxiracetam, piracetam or citicoline sodium. The medication needs to be under the direction of doctors.
2. Non-drug treatment: there are many ways of non-drug treatment, including nursing, nutrition supplementing, cognitive rehabilitation training or physical training, etc., which can improve the memory and cognitive ability of the patient, thereby achieving the therapeutic effect. Meanwhile, the senile dementia-prevention health care food is used for supporting the senile patients to participate in social activities and improving the mental condition of the patients, so that the life quality of the senile dementia patients is improved.
Senile dementia belongs to common diseases of the elderly, and seriously affects the physical health and life quality of patients. The senile dementia patient does not need to take medicine by oneself, recommends to visit a hospital in time, carries out scientific and reasonable treatment under the guidance of doctors, and is in line with doctor's advice, thereby avoiding delaying the illness state. The existing treatment method has the defect of treating the symptoms and not the root cause. Research has shown that antioxidants can prevent the occurrence of senile dementia through a number of pathways. First, antioxidants can neutralize harmful free radicals, alleviate oxidative damage to cells, and thereby protect cell function from damage. Secondly, antioxidants can also inhibit inflammation and abnormal neurogenetic activities, slowing down processes such as apoptosis and neuronal degeneration. In addition, antioxidants can also improve brain cell metabolism, increase brain cell energy supply, and help neurons to continue to maintain their function. In summary, how to provide a treatment method for senile dementia with good treatment effect and no toxic or side effect is a problem to be solved by the technicians in the field.
Disclosure of Invention
In view of the above, the invention provides a compound American ginseng antioxidant product, a composition for treating senile dementia and a preparation method thereof.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
a compound antioxidation product containing American ginseng is prepared by extracting the following components in parts by weight: 20-30 parts of American ginseng, 15-25 parts of prepared rehmannia root, 20-28 parts of dogwood, 15-25 parts of baical skullcap root, 15-25 parts of gardenia, 8-12 parts of safflower, 18-22 parts of szechuan lovage rhizome, 20-26 parts of bitter orange, 18-25 parts of grassleaf sweetflag rhizome, 10-20 parts of polygala tenuifolia, 16-26 parts of platycladi seed and 15-25 parts of wild jujube seed.
The American ginseng-containing compound antioxidation product is prepared by extracting the following components in parts by weight: 20 parts of American ginseng, 25 parts of prepared rhizome of rehmannia, 20 parts of dogwood, 25 parts of baical skullcap root, 15 parts of cape jasmine, 12 parts of safflower, 18 parts of szechuan lovage rhizome, 26 parts of bitter orange, 18 parts of grassleaf sweelflag rhizome, 20 parts of thinleaf milkwort root-bark, 16 parts of platycladi seed and 25 parts of wild jujube seed.
The preparation method of the American ginseng-containing compound antioxidant product comprises the following steps:
(1) Selecting and weighing: selecting raw materials, and removing impurities and unqualified products;
(2) Cleaning, drying and crushing: cleaning the raw materials obtained in the step (1) respectively, drying, crushing, sieving and weighing to obtain powdery medicaments;
(3) Mixing safflower powder, szechuan lovage rhizome powder, platycladi seed powder and wild jujube seed powder to obtain a mixture A, adding ethanol with the mass of 10-12 times of that of the mixture A, carrying out reflux extraction for 2 times, carrying out reflux extraction for 2-3 hours each time, combining the extracting solutions, filtering, and concentrating the filtrate under reduced pressure to obtain an alcohol extraction concentrate;
(4) Mixing the rest medicinal materials to obtain a mixture B, adding water 10-20 times of the mixture B, adding the residues obtained in the step (3), soaking for 1-2 h, and decocting for 3 times each for 1-2 h;
(5) Mixing the three water decoctions, mixing with the ethanol extract concentrate obtained in step (3), concentrating under reduced pressure, and vacuum drying to obtain dry extract powder.
The American ginseng-containing compound antioxidation product is prepared by extracting the following components in parts by weight: 25 parts of American ginseng, 20 parts of prepared rehmannia root, 24 parts of dogwood, 20 parts of baical skullcap root, 20 parts of cape jasmine, 10 parts of safflower, 20 parts of szechuan lovage rhizome, 23 parts of bitter orange, 21 parts of grassleaf sweelflag rhizome, 15 parts of thinleaf milkwort root-bark, 20 parts of platycladi seed and 20 parts of wild jujube seed.
The preparation method of the American ginseng-containing compound antioxidant product comprises the following steps:
(1) Selecting and weighing: selecting raw materials, and removing impurities and unqualified products;
(2) Cleaning, drying and crushing: cleaning the raw materials obtained in the step (1) respectively, drying, crushing, sieving and weighing to obtain powdery medicaments;
(3) Mixing safflower powder, szechuan lovage rhizome powder, platycladi seed powder and wild jujube seed powder to obtain a mixture A, adding ethanol with the mass of 10-12 times of that of the mixture A, carrying out reflux extraction for 2 times, carrying out reflux extraction for 2-3 hours each time, combining the extracting solutions, filtering, and concentrating the filtrate under reduced pressure to obtain an alcohol extraction concentrate;
(4) Mixing the rest medicinal materials to obtain a mixture B, adding water 10-20 times of the mixture B, adding the residues obtained in the step (3), soaking for 1-2 h, and decocting for 3 times each for 1-2 h;
(5) Mixing the three water decoctions, mixing with the ethanol extract concentrate obtained in step (3), concentrating under reduced pressure, and vacuum drying to obtain dry extract powder.
The drying temperature in the step (2) is 40-60 ℃, the compound antioxidant product containing American ginseng is sieved to pass through a 80-100-mesh sieve, and the volume concentration of the ethanol in the step (3) is 80-90%.
The preparation method of the American ginseng-containing compound antioxidant product also comprises the step of adding excipients into the dry extract powder to prepare tablets, capsules or granules.
The excipient in the preparation method of the American ginseng-containing compound antioxidant product is one or more of dextrin, mannitol, sucrose, xylitol and starch.
The compound antioxidation product containing American ginseng is applied to the preparation of antioxidation medicines.
The application of the American ginseng-containing compound antioxidant product in preparing a medicine for improving memory is provided.
The application of the American ginseng-containing compound antioxidant product in preparing medicines for treating senile dementia.
American ginseng, poria cocos, chinese yam, prepared rhizome of rehmannia, dogwood, scutellaria baicalensis, fructus gardeniae, safflower, ligusticum wallichii, fructus aurantii, rhizoma acori graminei, polygala tenuifolia, platycladi seed and spina date seed all accord with Chinese pharmacopoeia.
Poria cocos is sweet and light in taste and flat. It enters heart, spleen and kidney meridians. Has effects of promoting diuresis, removing dampness, invigorating spleen, and tranquilizing. Can be used for treating edema, diarrhea, dysuria, phlegm retention, palpitation, and insomnia.
The prepared rehmannia root has sweet and slightly warm nature, enters liver and kidney meridians, has the effects of nourishing blood and yin, replenishing essence and replenishing marrow, and is suitable for blood deficiency syndrome, irregular menstruation of women, liver and kidney yin deficiency syndrome, diabetes syndrome, essence and blood deficiency syndrome and the like. The prepared rehmannia root is an important medicine for nourishing liver and kidney, and can nourish blood, nourish yin, and produce sperm and fill marrow. According to traditional Chinese medicine, essence and blood are the most fundamental substance foundation in a human body, and liver and kidney functions are normal when essence and blood are sufficient, so that the body shows a strong functional state. Conversely, dizziness and soreness of the waist and knees may occur when the human body is deficient in essence and blood. Modern medical research proves that prepared rehmannia root contains sitosterol, mannitol, rehmannia root, saccharides, various vitamins and minerals and the like. The prepared rehmannia root has the effects of inhibiting lipid peroxidation, improving antioxidant enzyme activity and the like, and can reduce blood pressure, blood fat, inhibit thrombosis, improve myocardial ischemia and the like.
Chuan Xiong is pungent in flavor and warm in nature. Enter liver, gallbladder and pericardium meridians. Has effects of promoting blood circulation, activating qi-flowing, dispelling pathogenic wind, and relieving pain. Can be used for soothing nerves, relieving headache, abdominal pain, stabbing pain in chest and hypochondrium, and headache.
The radix salviae miltiorrhizae has the effects of promoting blood circulation, removing blood stasis, dredging channels, relieving pain, clearing heart fire, relieving restlessness and cooling blood. Can be used for treating pain in the stomach, abdomen, hypochondrium, vexation, insomnia, menoxenia, and swelling and pain.
Wolfberry fruit is neutral in nature and sweet in taste. Enter liver meridian, kidney meridian and lung meridian. Has effects of nourishing liver and kidney, improving eyesight, and moistening lung. Can be used for treating dizziness, dim eyesight, spermatorrhea, diabetes, and cough due to yin deficiency.
American ginseng is the dry root of American ginseng Panax quinquefolium L. All are cultivated products, which are collected in autumn, washed, dried in the sun or dried at low temperature. It enters heart, lung and kidney meridians. Sweet, slightly bitter and cool. Replenishing qi, nourishing yin, clearing heat and promoting fluid production. Can be used for treating deficiency of qi and yin, internal heat, cough, asthma, phlegm, dysphoria due to deficiency heat, diabetes, dry mouth, and dry throat.
The principle of traditional Chinese medicine for treating senile dementia is formulated according to the knowledge of the pathogenesis of dementia. The brain is thought to be the house of the spirit and the mind is not in the heart. In the case of the high-year-old-no-memory, the brain is gradually emptied. The essence and mind of the person are both hidden in the kidney, and the deficiency of essence leads to the failure of the aspiration to communicate with the heart, so the person is confused and forgets. In TCM, it is also considered that any of the avermectins is free of phlegm and gradually causes dementia by stagnation, by paralysis, by anxiety, or by panic. Heart qi deficiency, poor spirit and phlegm, and excessive and forgetful phlegm due to the heart-qi deficiency. The heart is also forgotten due to stagnant blood. From the above discussion, it is known that senile dementia is thought to be in brain, and has close relationship with viscera disorders such as heart, liver, spleen and kidney, and is caused by deficiency of qi, blood, phlegm, stagnation and fire. Is characterized by heart-kidney-spleen deficiency, phlegm stagnation, heart as the principal organ, and the deficiency of qi and blood, malnutrition of the brain, which leads to mental dispersion, unconsciousness and amnesia. Kidneys are the congenital origin, kidneys govern bones, bone marrow generation and marrow communication, and kidney essence and qi are the important material basis of the brain. Kidney essence deficiency and malnutrition of the brain can lead to confusion, amnesia, slow movement and slow reaction. Secondly, seven emotions hurt the liver, liver qi stagnation, or spleen failing to transport and stagnate water dampness, which is prone to phlegm and fire. The phlegm stagnation is a pathogenic qi that can cause dementia when it is blocked in the five zang organs.
The invention considers that senile dementia patients often have senile diseases, deficiency of qi and blood, spleen and kidney, biochemical hyposource and marrow sea deficiency, so American ginseng, tuckahoe and yam are used for replenishing qi to invigorate the spleen, and rehmannia glutinosa and dogwood are used as monarch drugs; moreover, senile dementia is usually caused by qi depression for a long time, fire is removed, yin is burned, or blood stasis is blocked in brain collaterals, and brain qi cannot be connected with dirty gas phase, so that the senile dementia is forgetful, and the baical skullcap root, the cape jasmine fruit, the safflower, the szechuan lovage rhizome and the bitter orange are used as ministerial drugs for clearing away heart-fire and detoxifying, and the safflower, the szechuan lovage rhizome and the bitter orange are used for promoting blood circulation and promoting qi; also, because spleen and stomach are weak and phlegm is not transformed, phlegm is accumulated in the chest, the orifices of qingling are shielded, grassleaf sweelflag rhizome and polygala tenuifolia are adopted as adjuvant drugs, platycladi seed and spina date seed are adopted as guiding drugs for nourishing heart and soothing nerves, and the medicine has the effects of resisting oxidization and improving memory aiming at the vexation and irritability and restlessness of the patients suffering from senile dementia through experimental researches in the whole formula, and can treat senile dementia.
Detailed Description
The following description of the technical solutions in the embodiments of the present invention will be clear and complete, and it is obvious that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
The required medicament is a conventional experimental medicament and is purchased from a commercial channel; the test methods not mentioned are conventional test methods and will not be described in detail herein.
Example 1
The formula comprises the following components: 20g of American ginseng, 25g of prepared rehmannia root, 20g of dogwood, 25g of baical skullcap root, 15g of gardenia, 12g of safflower, 18g of szechuan lovage rhizome, 26g of bitter orange, 18g of grassleaf sweelflag rhizome, 20g of thinleaf milkwort root-bark, 16g of platycladi seed and 25g of wild jujube seed.
The preparation method comprises the following steps:
(1) Selecting and weighing: selecting raw materials, and removing impurities and unqualified products;
(2) Cleaning, drying and crushing: cleaning the raw materials obtained in the step (1) respectively, drying (drying temperature is 40 ℃), crushing, sieving with a 80-mesh sieve, and weighing to obtain powdery medicines;
(3) Mixing Carthami flos powder, rhizoma Ligustici Chuanxiong powder, semen Platycladi powder and semen Ziziphi Spinosae powder, adding 80% ethanol 10 times of the materials, reflux extracting for 2 times, reflux extracting for 2 hr each time, mixing extractive solutions, filtering, concentrating the filtrate under reduced pressure to obtain ethanol extractive solution;
(4) Mixing the rest medicinal materials, adding water 20 times of the medicinal materials, adding the medicinal residues obtained in the step (3), soaking for 1h, and decocting for 3 times each for 2h;
(5) Mixing the three water decoctions, mixing with the ethanol extract concentrate obtained in step (3), concentrating under reduced pressure, vacuum drying to obtain dry extract powder, adding dextrin, and making into granule.
Example 2
The formula comprises the following components: 30g of American ginseng, 15g of rehmannia glutinosa, 28g of dogwood, 15g of baical skullcap root, 25g of cape jasmine fruit, 8g of safflower, 22g of szechuan lovage rhizome, 20g of bitter orange, 25g of grassleaf sweelflag rhizome, 10g of thinleaf milkwort root-bark, 26g of platycladi seed and 15g of wild jujube seed.
The preparation method comprises the following steps:
(1) Selecting and weighing: selecting raw materials, and removing impurities and unqualified products;
(2) Cleaning, drying and crushing: cleaning the raw materials obtained in the step (1) respectively, drying (drying temperature is 60 ℃), crushing, sieving with a 100-mesh sieve, and weighing to obtain powdery medicines;
(3) Mixing Carthami flos powder, rhizoma Ligustici Chuanxiong powder, semen Platycladi powder and semen Ziziphi Spinosae powder, adding 90% ethanol 12 times of the materials, reflux extracting for 2 times, reflux extracting for 3 hr each time, mixing extractive solutions, filtering, concentrating the filtrate under reduced pressure to obtain ethanol extractive solution;
(4) Mixing the rest medicinal materials, adding water 10 times of the medicinal materials, adding the medicinal residues obtained in the step (3), soaking for 1h, and decocting for 3 times each for 1h;
(5) Mixing the three water decoctions, mixing with the ethanol extract concentrate obtained in step (3), concentrating under reduced pressure, vacuum drying to obtain dry extract powder, adding dextrin, and making into granule.
Example 3
The formula comprises the following components: 20g of American ginseng, 25g of prepared rehmannia root, 20g of dogwood, 25g of baical skullcap root, 15g of gardenia, 12g of safflower, 18g of szechuan lovage rhizome, 26g of bitter orange, 18g of grassleaf sweelflag rhizome, 20g of thinleaf milkwort root-bark, 16g of platycladi seed and 25g of wild jujube seed.
The preparation method comprises the following steps:
(1) Selecting and weighing: selecting raw materials, and removing impurities and unqualified products;
(2) Cleaning, drying and crushing: cleaning the raw materials obtained in the step (1) respectively, drying (drying temperature is 50 ℃), crushing, sieving with a 90-mesh sieve, and weighing to obtain a powdery medicament;
(3) Mixing Carthami flos powder, rhizoma Ligustici Chuanxiong powder, semen Platycladi powder and semen Ziziphi Spinosae powder, adding 85% ethanol 12 times of the materials, reflux extracting for 2 times and 2.5 hr each time, mixing extractive solutions, filtering, concentrating the filtrate under reduced pressure to obtain ethanol extractive solution;
(4) Mixing the rest medicinal materials, adding water 20 times of the medicinal materials, adding the medicinal residues obtained in the step (3), soaking for 2h, and decocting for 3 times each for 1h;
(5) Mixing the three water decoctions, mixing with the ethanol extract concentrate obtained in step (3), concentrating under reduced pressure, vacuum drying, making into dry extract powder, adding mannitol, and making into tablet.
Example 4
The formula comprises the following components: 20g of American ginseng, 25g of prepared rehmannia root, 20g of dogwood, 25g of baical skullcap root, 15g of gardenia, 12g of safflower, 18g of szechuan lovage rhizome, 26g of bitter orange, 18g of grassleaf sweelflag rhizome, 20g of thinleaf milkwort root-bark, 16g of platycladi seed and 25g of wild jujube seed.
The preparation method comprises the following steps:
(1) Selecting and weighing: selecting raw materials, and removing impurities and unqualified products;
(2) Cleaning, drying and crushing: cleaning the raw materials obtained in the step (1) respectively, drying (drying temperature is 60 ℃), crushing, sieving with a 100-mesh sieve, and weighing to obtain powdery medicines;
(3) Mixing Carthami flos powder, rhizoma Ligustici Chuanxiong powder, semen Platycladi powder and semen Ziziphi Spinosae powder, adding 90% ethanol 10 times of the materials, reflux extracting for 2 times, reflux extracting for 2 hr each time, mixing extractive solutions, filtering, concentrating the filtrate under reduced pressure to obtain ethanol extractive solution;
(4) Mixing the rest medicinal materials, adding water 20 times of the medicinal materials, adding the medicinal residues obtained in the step (3), soaking for 1h, and decocting for 3 times each for 2h;
(5) Mixing the three water decoctions, mixing with the ethanol extract concentrate obtained in step (3), concentrating under reduced pressure, vacuum drying to obtain dry extract powder, adding xylitol, and making into capsule.
Example 5
The formula comprises the following components: 20g of American ginseng, 25g of prepared rehmannia root, 20g of dogwood, 25g of baical skullcap root, 15g of gardenia, 12g of safflower, 18g of szechuan lovage rhizome, 26g of bitter orange, 18g of grassleaf sweelflag rhizome, 20g of thinleaf milkwort root-bark, 16g of platycladi seed and 25g of wild jujube seed.
The preparation method comprises the following steps:
(1) Selecting and weighing: selecting raw materials, and removing impurities and unqualified products;
(2) Cleaning, drying and crushing: cleaning the raw materials obtained in the step (1) respectively, drying (drying temperature is 60 ℃), crushing, sieving with a 80-mesh sieve, and weighing to obtain powdery medicines;
(3) Mixing Carthami flos powder, rhizoma Ligustici Chuanxiong powder, semen Platycladi powder and semen Ziziphi Spinosae powder, adding 80% ethanol 12 times of the materials, reflux extracting for 2 times, reflux extracting for 2 hr each time, mixing extractive solutions, filtering, concentrating the filtrate under reduced pressure to obtain ethanol extractive solution;
(4) Mixing the rest medicinal materials, adding water 20 times of the medicinal materials, adding the medicinal residues obtained in the step (3), soaking for 1h, and decocting for 3 times each for 2h;
(5) Mixing the three water decoctions, mixing with the ethanol extract concentrate obtained in step (3), concentrating under reduced pressure, vacuum drying to obtain dry extract powder, adding starch, and making into granule.
Experimental example 1: the invention relates to an experimental study on the effect of a mouse memory acquisition disorder model caused by scopolamine, and the method has the following results:
1 Experimental materials
72 male mice of Kunming species, 18-22g in weight, animals at constant temperature (21-23 ℃), constant humidity (45-65%), artificial day and night, ordinary feed feeding and free drinking. The granules prepared in the embodiment 1 of the present invention (low dose group 1g/kg.bw, medium dose group 2g/kg.bw, high dose group 4 g/kg.bw) were randomly divided into 6 groups, namely, a control group, a model group and a positive drug group (donepezil hydrochloride 0.65 mg/kg), and the control group and the model group were given an equivalent amount of physiological saline, and after 10 minutes, a memory test was performed, and the study and memory conditions of mice were tested by using a diving tower method and a water maze method.
2 experimental methods and observation indexes.
2.1 diving tower method: and (3) placing the mice in each group on a mouse diving tower instrument, adapting to a voltage environment for 3 minutes, then continuously electrically stimulating for 5 minutes at 36V, taking the normal escape response of the mice after electric shock as jumping up of the rubber tower, and recording the times of jumping down of the rubber tower by the animals within 5 minutes as the error times of the training period. The training is performed in parallel. The mice were re-recorded after 24 hours, the first time to jump down (latency) was recorded, and the number of jumps down (i.e. number of errors) within 5 minutes was recorded as a memory indicator.
2.2 Water maze method: the water temperature in the Y-shaped water pump road box of the mouse is maintained to be 25-27 ℃ and the water depth is about 1 cm. The mice of each group are respectively put into the water labyrinth for training, when in training, the mice are slightly put into the water surface from the tail of the long arm to the Y-shaped fork, the mice arrive at the platform within 15 seconds as correct response, and after the mice arrive at the platform, the mice rest for 15 seconds and then are repeatedly trained, and the training is connected for 6 times. The time from entry of water to arrival at the platform was recorded for the mice to walk out and the correct number of responses. After 24 hours, the memory retention was tested and after 48 hours the memory consolidation was tested.
2.3 detection of SOD Activity and MDA level in mouse brain tissue: after the water maze experiment is finished, 10 mice are randomly selected from each group, brain tissues are taken after anesthesia by intraperitoneal injection of 10% chloral hydrate, homogenate is obtained after cleavage, centrifugation is carried out for 10 minutes at 12000 rpm, supernatant is reserved, and MDA level and SOD activity detection of the brain tissues of the mice are detected by adopting an ELISA method.
3 results
3.1 bench jump test results are shown in Table 1
Table 1 results of the test conducted in the diving tower method (x.+ -. S, n=10) for each group of mice
Group of Diving tower latency period(s) Number of errors (n)
Normal control group 234.5±79.6 1.2±1.34
Model control group 57.8±53.8 14.8±7.19
Positive control group 198.4±84.2* 3.7±2.63*
The low dose group of the invention 156.9±57.4* 7.4±4.32*
Dosage unit of the invention 187.5±47.5* 5.6±2.98*
The high dose group of the invention 204.7±83.8* 3.50±2.42*
Note that: p <0.05 compared to model control.
The diving platform latency of the mice of the comparison group of the diving platform test result model is obviously shortened, and the error frequency is obviously increased; the administration groups of the invention can obviously prolong the diving platform latency of the mice, obviously reduce the diving platform error times of the mice and have dose correlation.
3.2 Water maze test results are shown in Table 2
Table 2 results of the water maze method for mice of each group (x±s, n=10)
Group of Number of correct reactions on day 1 Number of correct reactions on day 2 Number of correct reactions on day 3
Normal control group 5.25±1.36 6.09±1.98 7.23±1.56
Model control group 0.87±1.53 1.45±1.76 1.82±1.48
Positive control group 2.67±1.72** 3.42±1.33** 4.02±1.08**
The low dose group of the invention 1.76±1.48* 2.56±1.21* 3.43±1.25**
Dosage unit of the invention 2.63±1.24** 3.46±1.66** 2.98±1.04*
The high dose group of the invention 3.53±1.55** 2.98±1.23* 4.53±1.76**
Note that: p <0.05, < P <0.01 compared to model control.
Water maze test results three consecutive days the water maze test found: the time required for the model group to move the maze is obviously higher than that of the model group (P < 0.01) compared with the normal control group, and the time required for the model group to move the maze is obviously lower than that of the model group (P <0.05 or P < 0.01) according to each dose group, so that the model group has dose correlation.
3.3 results of SOD activity and MDA level content determination in brain tissue of mice are shown in Table 3
Table 3 determination of SOD activity and MDA levels in mouse brain tissue (x±s, n=10)
Group of SOD(ng/mL) MDA(nmol/mL)
Normal control group 3.56±0.78 0.96±0.09
Model control group 2.23±0.26 1.43±0.34
Positive control group 3.42±1.53* 1.14±0.53*
The low dose group of the invention 2.56±0.34* 1.34±0.94*
Dosage unit of the invention 3.09±1.02* 1.25±0.45*
The inventionMing Gao dose group 3.27±1.24** 1.17±0.29**
Note that: p <0.05, P <0.01 compared to model control.
Experimental results of SOD activity and MDA level content in brain tissues of mice show that compared with a blank group, the model control group has obviously increased MDA level and obviously reduced SOD activity; compared with the model group, each group can improve SOD activity (P <0.05, P < 0.01). The effect of the invention for treating senile dementia is possibly acted by antioxidation.
Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims (10)

1. The compound antioxidant product containing American ginseng is characterized by being prepared by extracting the following components in parts by weight: 20-30 parts of American ginseng, 15-25 parts of prepared rehmannia root, 20-28 parts of dogwood, 15-25 parts of baical skullcap root, 15-25 parts of gardenia, 8-12 parts of safflower, 18-22 parts of szechuan lovage rhizome, 20-26 parts of bitter orange, 18-25 parts of grassleaf sweetflag rhizome, 10-20 parts of polygala tenuifolia, 16-26 parts of platycladi seed and 15-25 parts of wild jujube seed.
2. The American ginseng-containing compound antioxidation product according to claim 1, which is characterized by being prepared by extracting the following components in parts by weight: 20 parts of American ginseng, 25 parts of prepared rhizome of rehmannia, 20 parts of dogwood, 25 parts of baical skullcap root, 15 parts of cape jasmine, 12 parts of safflower, 18 parts of szechuan lovage rhizome, 26 parts of bitter orange, 18 parts of grassleaf sweelflag rhizome, 20 parts of thinleaf milkwort root-bark, 16 parts of platycladi seed and 25 parts of wild jujube seed.
3. The compound antioxidant product containing American ginseng according to claim 1, wherein the preparation method comprises the following steps:
(1) Selecting and weighing: selecting raw materials, and removing impurities and unqualified products;
(2) Cleaning, drying and crushing: cleaning the raw materials obtained in the step (1) respectively, drying, crushing, sieving and weighing to obtain powdery medicaments;
(3) Mixing safflower powder, szechuan lovage rhizome powder, platycladi seed powder and wild jujube seed powder to obtain a mixture A, adding ethanol with the mass of 10-12 times of that of the mixture A, carrying out reflux extraction for 2 times, carrying out reflux extraction for 2-3 hours each time, combining the extracting solutions, filtering, and concentrating the filtrate under reduced pressure to obtain an alcohol extraction concentrate;
(4) Mixing the rest medicinal materials to obtain a mixture B, adding water 10-20 times of the mixture B, adding the residues obtained in the step (3), soaking for 1-2 h, and decocting for 3 times each for 1-2 h;
(5) Mixing the three water decoctions, mixing with the ethanol extract concentrate obtained in step (3), concentrating under reduced pressure, and vacuum drying to obtain dry extract powder.
4. The American ginseng-containing compound antioxidation product according to claim 1, which is characterized by being prepared by extracting the following components in parts by weight: 25 parts of American ginseng, 20 parts of prepared rehmannia root, 24 parts of dogwood, 20 parts of baical skullcap root, 20 parts of cape jasmine, 10 parts of safflower, 20 parts of szechuan lovage rhizome, 23 parts of bitter orange, 21 parts of grassleaf sweelflag rhizome, 15 parts of thinleaf milkwort root-bark, 20 parts of platycladi seed and 20 parts of wild jujube seed.
5. The compound antioxidant product containing American ginseng according to claim 4, wherein the preparation method comprises the following steps:
(1) Selecting and weighing: selecting raw materials, and removing impurities and unqualified products;
(2) Cleaning, drying and crushing: cleaning the raw materials obtained in the step (1) respectively, drying, crushing, sieving and weighing to obtain powdery medicaments;
(3) Mixing safflower powder, szechuan lovage rhizome powder, platycladi seed powder and wild jujube seed powder to obtain a mixture A, adding ethanol with the mass of 10-12 times of that of the mixture A, carrying out reflux extraction for 2 times, carrying out reflux extraction for 2-3 hours each time, combining the extracting solutions, filtering, and concentrating the filtrate under reduced pressure to obtain an alcohol extraction concentrate;
(4) Mixing the rest medicinal materials to obtain a mixture B, adding water 10-20 times of the mixture B, adding the residues obtained in the step (3), soaking for 1-2 h, and decocting for 3 times each for 1-2 h;
(5) Mixing the three water decoctions, mixing with the ethanol extract concentrate obtained in step (3), concentrating under reduced pressure, and vacuum drying to obtain dry extract powder.
6. The compound antioxidant product containing American ginseng according to claim 3 or 5, wherein the drying temperature in the step (2) in the preparation method is 40-60 ℃, the product is sieved by a sieve of 80-100 meshes, and the volume concentration of the ethanol in the step (3) in the preparation method is 80-90%.
7. The compound antioxidant product containing American ginseng according to claim 3 or 5, wherein the preparation method further comprises the step of adding an excipient into the extract dry powder to prepare tablets, capsules or granules.
8. The compound antioxidant product containing American ginseng according to claim 7, wherein the excipient is one or more of dextrin, mannitol, sucrose, xylitol and starch.
9. The use of the compound antioxidant product containing American ginseng according to claim 1 in the preparation of antioxidant medicines.
10. The use of the compound antioxidant product containing American ginseng according to claim 1 in preparing a memory function regulating product.
CN202310689265.6A 2023-06-12 2023-06-12 Compound antioxidant product containing American ginseng and preparation method and application thereof Active CN116549543B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310689265.6A CN116549543B (en) 2023-06-12 2023-06-12 Compound antioxidant product containing American ginseng and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310689265.6A CN116549543B (en) 2023-06-12 2023-06-12 Compound antioxidant product containing American ginseng and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN116549543A CN116549543A (en) 2023-08-08
CN116549543B true CN116549543B (en) 2024-04-12

Family

ID=87494785

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310689265.6A Active CN116549543B (en) 2023-06-12 2023-06-12 Compound antioxidant product containing American ginseng and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN116549543B (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408397A (en) * 2001-09-26 2003-04-09 北京本元青阳生物科技发展有限公司 Composition containing melatonin and galangal fruit traditional Chinese medicine
KR20040023197A (en) * 2002-09-11 2004-03-18 백일성 Phamaceutical use for treating Alzheimer of composition comprising, as main ingredients, Aurantii Nobilis Pericarpium, Hoelen, Ligusticum acutilobum, Uncariae Ramulus et Uncus, Acorus gramineus, Atractyodis Rhizoma, Angelica dahurica, Zizyphi Spinosi Semen, Rehmanniae Radix Preparata, Cornus officinalis, Polygala tenuifolia pharmaceutical preparations containing them
CN105287990A (en) * 2015-10-10 2016-02-03 南京中医药大学 Traditional Chinese medicinal preparation for preventing and treating senile dementia and preparation method of traditional Chinese medicinal preparation
CN108096422A (en) * 2018-01-31 2018-06-01 横琴恩健生物科技有限公司 A kind of Chinese medicine composition for treating senile dementia and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1408397A (en) * 2001-09-26 2003-04-09 北京本元青阳生物科技发展有限公司 Composition containing melatonin and galangal fruit traditional Chinese medicine
KR20040023197A (en) * 2002-09-11 2004-03-18 백일성 Phamaceutical use for treating Alzheimer of composition comprising, as main ingredients, Aurantii Nobilis Pericarpium, Hoelen, Ligusticum acutilobum, Uncariae Ramulus et Uncus, Acorus gramineus, Atractyodis Rhizoma, Angelica dahurica, Zizyphi Spinosi Semen, Rehmanniae Radix Preparata, Cornus officinalis, Polygala tenuifolia pharmaceutical preparations containing them
CN105287990A (en) * 2015-10-10 2016-02-03 南京中医药大学 Traditional Chinese medicinal preparation for preventing and treating senile dementia and preparation method of traditional Chinese medicinal preparation
CN108096422A (en) * 2018-01-31 2018-06-01 横琴恩健生物科技有限公司 A kind of Chinese medicine composition for treating senile dementia and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
健忘症的中医方法与食疗;刘继林;中华养生保健;20221231;-(06);27-28 *
治疗老年痴呆病中药应用频次及临床分析;石景洋;付卫云;毛秉豫;李凤芝;;中国实验方剂学杂志;20130420;19(08);355-361 *
补肾益聪汤治疗老年痴呆20例;汪美荣;河南中医;20040510;24(05);32-33 *

Also Published As

Publication number Publication date
CN116549543A (en) 2023-08-08

Similar Documents

Publication Publication Date Title
US7968128B2 (en) Plant extract compositions for affecting sleep
CN103520621B (en) A kind of Chinese medicine composition for the treatment of senile cataract and preparation method thereof
CN103719493B (en) Siberian solomonseal rhizome health-care tea of a kind of brain-nourishing intelligence-benefiting and preparation method thereof
CN102988905B (en) Traditional Chinese medicine preparation for treating epilepsia and preparation method thereof
CN102462753B (en) Traditional Chinese medicine composition capable of treating cervical vertigo and preparation method thereof
CN116509971A (en) Traditional Chinese medicine formula, traditional Chinese medicine liquid and medicinal preparation with intelligence improving effect
CN116549543B (en) Compound antioxidant product containing American ginseng and preparation method and application thereof
CN115350256B (en) Traditional Chinese medicine composition for treating insomnia and preparation method thereof
CN101306138A (en) Chinese traditional injection preparation for treating chest stuffiness and pains and its preparation method
CN109966379A (en) A kind of pharmaceutical composition and preparation method thereof for insomnia
CN112316051B (en) Traditional Chinese medicine composition for nourishing blood and reducing phlegm as well as traditional Chinese medicine preparation, preparation method and application thereof
CN109481656B (en) Medicine for treating senile dementia
CN112807398A (en) Traditional Chinese medicine composition with effects of nourishing yin, clearing heat, nourishing blood and soothing nerves
CN107375829A (en) Treat the Chinese medicine composition of Post-apoplectic and its preparation method of preparation
CN103656164A (en) Traditional Chinese medicine composition for nourishing yin, nourishing blood, tonifying heart and soothing nerves and preparation method thereof
CN104666689A (en) Medicine for treating hypertension
CN105796927B (en) A kind of Chinese medicine composition for treating blepharospasm
CN100486621C (en) Chinese medicinal composition for treating hemilateral headache and its preparation method
CN103751283B (en) A kind of Chinese medicine composition for the treatment of cardiopalmus and preparation method thereof
CN109758506B (en) Traditional Chinese medicine health food with function of improving sleep and preparation method thereof
CN103479868B (en) Traditional Chinese medicine for treating apprehensive and cowardly arrhythmia and preparation method
CN109106842B (en) A medicine for stopping smoking and its preparation method
CN116019891B (en) Traditional Chinese medicine ointment formula for treating tinnitus and deafness and preparation method thereof
CN106177389B (en) Traditional Chinese medicine preparation with functions of relaxing bowel, improving sleep and enhancing immunity and preparation method thereof
CN104547695B (en) It is a kind of for treating the pharmaceutical composition and its application of trigeminal neuralgia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant